AT378039T - Production method of particles for use in a pharmaceutical composition - Google Patents

Production method of particles for use in a pharmaceutical composition

Info

Publication number
AT378039T
AT378039T AT01947612T AT01947612T AT378039T AT 378039 T AT378039 T AT 378039T AT 01947612 T AT01947612 T AT 01947612T AT 01947612 T AT01947612 T AT 01947612T AT 378039 T AT378039 T AT 378039T
Authority
AT
Austria
Prior art keywords
particles
use
pharmaceutical composition
production method
production
Prior art date
Application number
AT01947612T
Other languages
German (de)
Inventor
John Staniforth
David Morton
Rosella Musa
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP00113608 priority Critical
Priority to GB0029263A priority patent/GB0029263D0/en
Priority to PCT/GB2001/001732 priority patent/WO2001078694A2/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of AT378039T publication Critical patent/AT378039T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT378039(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/958Drug, bio-affecting and body treating compositions for smoking or inhaling
AT01947612T 2000-04-17 2001-06-27 Production method of particles for use in a pharmaceutical composition AT378039T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00113608 2000-06-27
GB0029263A GB0029263D0 (en) 2000-11-30 2000-11-30 Method of making particles for use in a pharmaceutical composition
PCT/GB2001/001732 WO2001078694A2 (en) 2000-04-17 2001-04-17 Formulations for use in inhaler devices

Publications (1)

Publication Number Publication Date
AT378039T true AT378039T (en) 2007-11-15

Family

ID=26071085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01947612T AT378039T (en) 2000-04-17 2001-06-27 Production method of particles for use in a pharmaceutical composition

Country Status (11)

Country Link
US (4) US7744855B2 (en)
EP (3) EP1296651B2 (en)
KR (1) KR100949539B1 (en)
CN (1) CN100551358C (en)
AT (1) AT378039T (en)
DK (1) DK1913939T3 (en)
ES (2) ES2632461T3 (en)
HK (1) HK1056115A1 (en)
IL (2) IL153705D0 (en)
PT (2) PT1296651E (en)
WO (1) WO2002000197A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
DK1337240T4 (en) 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
EP1296651B2 (en) * 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
PE12272001A1 (en) * 2000-04-17 2002-01-07 Chiesi Farma Spa Pharmaceutical formulations for DPIs in the form of hard agglomerates
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
AU2085702A (en) 2000-11-30 2002-06-11 Vectura Ltd Particles for use in a pharmaceutical composition
AU2002333644A1 (en) 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
GB0208742D0 (en) * 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CN102688224A (en) * 2003-04-14 2012-09-26 维克特拉有限公司 Device and pharmaceutical composition enhancing administration efficiency
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
CA2523475C (en) 2003-05-28 2013-02-05 Nektar Therapeutics Pharmaceutical formulation comprising a water-insoluble active agent
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
ES2243840T3 (en) 2003-07-25 2005-12-01 Ferring B.V. desmopressin pharmaceutical composition as solid dosage form and method for manufacturing the same.
WO2005025550A1 (en) * 2003-09-15 2005-03-24 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
DE102004011512A1 (en) * 2004-03-08 2005-09-22 Boehringer Ingelheim Vetmedica Gmbh A pharmaceutical preparation comprising pimobendan
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
CN101155590A (en) 2005-02-10 2008-04-02 葛兰素集团有限公司 Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
ITMI20051999A1 (en) 2005-10-21 2007-04-22 Eratech S R L Formulations of drugs in inhalation pierces dry powder for administration as such or with nebulizer and equipped with high deliverability 'breathability' and established '
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
DK2197429T3 (en) * 2007-09-03 2016-05-30 Nanotherapeutics Inc Particulate compositions for delivery of poorly soluble drugs
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
US9072664B2 (en) 2008-05-22 2015-07-07 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
US9956170B2 (en) 2008-06-26 2018-05-01 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
US9861580B2 (en) 2008-07-02 2018-01-09 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
KR20110089851A (en) 2008-11-25 2011-08-09 베링거잉겔하임베트메디카게엠베하 Phosphodiesterase type iii(pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
PT2410981T (en) 2009-03-26 2017-05-25 Pulmatrix Inc Dry powder formulations and methods for treating pulmonary diseases
CA2759041A1 (en) * 2009-04-24 2010-10-28 Schering Corporation Agglomerate formulations useful in dry powder inhalers
NZ620879A (en) 2009-04-24 2015-08-28 Iceutica Pty Ltd A novel formulation of indomethacin
JP6141013B2 (en) * 2009-04-24 2017-06-07 イシューティカ ピーティーワイ リミテッド Production of encapsulated nanoparticles on a commercial scale
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
KR20120104235A (en) * 2009-12-14 2012-09-20 키에시 파르마슈티시 엣스. 피. 에이. Antibiotic microparticles for inhalation
UA107499C2 (en) 2010-06-22 2015-01-12 Chiesi Farm Spa Dry powder formulation containing an antimuscarinic agent
CN106890165A (en) 2010-08-03 2017-06-27 奇斯药制品公司 Dry powder formulation comprising a phosphodiesterase inhibitor
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Company Inc Cationic dry powder
KR101915241B1 (en) 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 Monovalent metal cation dry powders for inhalation
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
TW201304822A (en) 2010-11-15 2013-02-01 Vectura Ltd Compositions and uses
WO2012073025A1 (en) 2010-11-30 2012-06-07 Vectura Limited Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
KR20150135328A (en) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 Tiotropium dry powders
ITMI20130571A1 (en) * 2013-04-10 2014-10-11 Zambon Spa A pharmaceutical composition containing budesonide and formoterol
ITMI20130572A1 (en) * 2013-04-10 2014-10-11 Eratech Srl Composition comprising at least two dry powders obtained by spray dry to increase the stability 'of the formulation
EP3021832A1 (en) 2013-07-19 2016-05-25 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CA2930033A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US9993488B2 (en) 2014-02-20 2018-06-12 Otitopic Inc. Dry powder formulations for inhalation
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CA2991760A1 (en) * 2014-07-31 2016-02-04 Otitopic Inc. Dry powder formulations for inhalation
CA2962531A1 (en) * 2014-10-08 2016-04-14 Eratech S.R.L. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349542A (en) 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa Pharmaceutical compositions for inhalation
SE8603812D0 (en) 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
DE3917617A1 (en) 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Micronized biodegradable particles, process for their preparation and their use
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
CA2115444C (en) * 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra The polypeptide formulation for inhalation further comprising an enhancer compound
AUPM414394A0 (en) * 1994-02-28 1994-03-24 Voxson International Pty. Limited Multi-mode communications system
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
DK0824344T3 (en) 1995-05-09 2005-08-15 Phoqus Pharmaceuticals Ltd A powdered composition for electrostatic coating of pharmaceutical substrates
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9526495D0 (en) 1995-12-23 1996-02-28 Knoll Ag Therapeutic agents
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5955023A (en) * 1996-11-27 1999-09-21 Callutech, Llc Method of forming composite particle products
DE69732306D1 (en) 1997-01-16 2005-02-24 Massachusetts Inst Technology Preparation of particle-containing medicinal products for inhalation
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP1066074A1 (en) * 1998-03-16 2001-01-10 Inhale Therapeutic Systems, Inc. Aerosolized active agent delivery
ME00189B (en) 1998-03-26 2011-02-10 Astellas Pharma Inc Sustained release preparations
DK1131059T3 (en) * 1998-11-13 2003-06-30 Jago Res Ag A dry powder for inhalation
GB9826783D0 (en) 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
JP5437543B2 (en) 1999-04-21 2014-03-12 1355540 オンタリオ インコーポレーテッド Asthma detection preparation
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
DE60044070D1 (en) * 1999-10-29 2010-05-06 Novartis Ag Dry powder compositions having improved dispersity
DK1337240T4 (en) * 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE12272001A1 (en) * 2000-04-17 2002-01-07 Chiesi Farma Spa Pharmaceutical formulations for DPIs in the form of hard agglomerates
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
EP1296651B2 (en) * 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
AU2085702A (en) 2000-11-30 2002-06-11 Vectura Ltd Particles for use in a pharmaceutical composition
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US20060147389A1 (en) 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US9192915B2 (en) * 2008-05-10 2015-11-24 Brigham Young University Porous composite particulate materials, methods of making and using same, and related apparatuses
AU2011209276B2 (en) * 2010-01-27 2015-02-12 Basf Se Coating means comprising composite particles
US8491908B2 (en) * 2010-06-01 2013-07-23 Canon Kabushiki Kaisha Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle

Also Published As

Publication number Publication date
IL153705A (en) 2011-02-28
EP1913939B1 (en) 2017-05-31
CN1438875A (en) 2003-08-27
US9351928B2 (en) 2016-05-31
IL153705D0 (en) 2003-07-06
KR100949539B1 (en) 2010-03-25
CN100551358C (en) 2009-10-21
PT1913939T (en) 2017-07-19
US20160243039A1 (en) 2016-08-25
EP2266549B1 (en) 2019-08-07
EP1296651B2 (en) 2019-07-17
KR20030051439A (en) 2003-06-25
ES2292598T3 (en) 2008-03-16
EP1913939A1 (en) 2008-04-23
ES2632461T3 (en) 2017-09-13
EP1296651A1 (en) 2003-04-02
EP2266549A2 (en) 2010-12-29
WO2002000197A1 (en) 2002-01-03
US7744855B2 (en) 2010-06-29
EP2266549A3 (en) 2012-01-18
DK1913939T3 (en) 2017-09-18
US20100285142A1 (en) 2010-11-11
US20180055772A1 (en) 2018-03-01
US20030162835A1 (en) 2003-08-28
PT1296651E (en) 2008-02-12
EP1296651B1 (en) 2007-11-14
HK1056115A1 (en) 2008-08-08

Similar Documents

Publication Publication Date Title
DE60239644D1 (en) A process for producing a probe card
DE60140736D1 (en) Honeycomb structure and method for making same
DE69927681D1 (en) Fluorescent granules, methods for production and use in tamper-proof papers
DE69943009D1 (en) A process for producing vitamin
AT275555T (en) A process for preparing dialkoxythiophenes and alkylenedioxythiophenes
DE60121335D1 (en) A method for increasing production of the fermentative erzeugnung of ethanol
DE60132937D1 (en) A process for the preparation of benzimidazol-2-yl -Chinolinonderivaten
AT405665T (en) A process for the production of ethanol
DE60129569D1 (en) A process for the production of synthesis gas with lanthanide-doped rhodium
DE60001944D1 (en) A process for the preparation of particles
DE60229283D1 (en) Continuous process for the production of ölsaatproteinisolat
DE60121922D1 (en) A method and composition for a suplantataufbau
DE60144380D1 (en) A method and equipment for the production of advanced composite structures
DE50115197D1 (en) A process for the manufacture of brushware and Brushware
AT382335T (en) A process for the preparation of microparticles for use in pharmaceutical compositions for inhalation
DE60233058D1 (en) Silsesquioxanderivate and process for their manufacture
DE60332281D1 (en) A process for the production of alumina-silica glasses and ceramics
DE60236642D1 (en) A process for the preparation of nanostructured materials
DE60027933D1 (en) A process for the production of steel
ATA10182002A (en) Diamond electrode and process for their manufacture
DE60208667D1 (en) A process for the production of platelet-
DE60117005D1 (en) Lithiummetallfluorophosphat-materials and methods for their production
DE69908655D1 (en) A process for the preparation of starch particles
DE60132239D1 (en) A process for the preparation of microparticles for use in pharmaceutical compositions for inhalation
DE60114318D1 (en) Capacitive humidity sensor and method for its production

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296651

Country of ref document: EP